Search

Filters

Clear Filters
3:20 PM - 3:30 PM ET

106 - Long-Term Follow-up Results for NRG/RTOG 0815: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer
Speaker: Krauss, Daniel, MD, FASTRO - Beaumont Health, Royal Oak, MI
3:05 PM - 3:10 PM ET

1060 - A Dynamic Priority-Aware Diffusion Model for Clinically-Driven Dose Prediction in Radiotherapy
Speaker: Yan, Xianrui, MS, M.Eng - Southeast University, Nanjing, shandong
3:10 PM - 3:15 PM ET

1061 - Adaptive Radiotherapy in Hypersensitive and High Locoregional Risk Breast Cancer: Preliminary Results of the SAHARA04 Phase II Trial
Speaker: Prunaretty, Jessica, MS - Institut du Cancer de Montpellier, Montpellier, Occitanie
3:15 PM - 3:20 PM ET

1062 - Interpretable Artificial Intelligence Decision Support Framework for Online Adaptive Radiotherapy Quality Assurance
Speaker: Winter, Jeff, PhD - Princess Margaret Cancer Centre, Toronto, Ontario
3:20 PM - 3:25 PM ET

1063 - From Feasibility to Clinical Practice: Direct-to-Treatment Ultra-Hypofractionated Whole-Breast ART with AI-Based Segmentation
Speaker: Tang, Shanshan, PhD - UT Southwestern Medical Center, Dallas, TX
3:25 PM - 3:30 PM ET

1064 - Assessment of Image Guidance and Adaptive Planning on the ART of SABR Phase II Trial for Near "Margin-Less" Adaptive Radiation Therapy of Primary Localized Prostate Cancer
Speaker: Morris, Toby, PhD - Mayo Clinic Rochester, Rochester, MN
5:05 PM - 5:10 PM ET

1066 - Rb1-S780 Phosphorylation as a Potential Biomarker for Grade 1.5 Meningiomas and Adjuvant Radiotherapy Decision Making
Speaker: Caglar, Hale Basak, MD - Memorial Goztepe Hospital, Istanbul, Istanbul
5:10 PM - 5:15 PM ET

1067 - Association of SMARCA4 Primary Tumor Mutations with Brain Metastases in Initially Non-Metastatic Non-Small Cell Lung Cancer
Speaker: Ellendula, Maneeth, BS - Yale School of Medicine, New Haven, CT
5:15 PM - 5:20 PM ET

1068 - Mutational Gene Signature Defines a High-Risk Subtype of Lung Adenocarcinoma with Genomic Instability and High Propensity for Brain Metastasis
Speaker: Zhang, Chuanbao - Stanford University, Palo Alto, CA
5:20 PM - 5:25 PM ET

1069 - The Impact of SETD2 Loss on Radiosensitivity and Survival in High-Grade Gliomas
Speaker: Suh, Won Young, MD - Seoul National University Hospital, Seoul, SEO
3:00 PM - 3:10 PM ET

107 - Co-Primary Endpoint Analysis for the INTREPId Randomized Trial of Prostate Radiation Therapy with Androgen Deprivation Therapy vs. Darolutamide Monotherapy
Speaker: King, Martin, MD, PhD - Brigham and Women's Hospital, Boston, MA
5:25 PM - 5:30 PM ET

1070 - Genomic Alterations and Intracranial Recurrence Patterns after Melanoma Brain Metastasis Resection
Speaker: Lee, James, BS - Memorial Sloan Kettering Cancer Center, Middletown Township, NJ